Member Info for BasilAlderman

You could also add Eccogene to that list. They were paid $185 million upfront 5 months ago for its Phase I candidate ECC5004 by AstraZeneca. The deal was structured with $185 million upfront and an additional $1.825bn in future payments from AZ. Phase 1 deals are becoming more and more common in the pharma sector. This bodes well for Sareum.

Yes, that's a good point about Eli Lilly licencing a P1 candidate last year for $40 Million. That could be replicated here. P1 candidates really are becoming more and more attractive to major pharma companies. e.g. AstraZeneca has entered in to a number of P1 licencing deals recently. It paid KYM Biosciences $63 Million upfront to licence its PI clinical candidate CMG901 & and agreed further milestone development and sales-related payments of up to $1.1bn with KYM. That's what we are looking at here for SDC-1801 and if it becomes a P2 candidate the value increases still further in to the hundreds of millions.

Yes, it looks like Bobbler is going to be right (again!) about 40p a share imminently. Probably tomorrow at this rate. We then go from 40p to 80p much quicker and from there to 160p with news. That's how this share price works. i.e. we are likely to see a repeat of 2021's mega surge if the P1a news from Oz is as promising as we expect it to be.

Yes, the excitement is gaining momentum with P1a data due from Oz very soon. Those that understand this share will know that SAR gained x46 approx from .2p to 9p+ in pre consolidation money (or from 10p to 450p+ in post consolidation money). i.e. A 4,600% gain. Excellent returns were made by many on here during the x 4,600% rise and surprise surprise the current share price is back where it was pre the mega rise. Just in time for data to be released.

For newbies, here's some background:

1. Sareum is a company that has all its global patent ducks in a row.

2. Sareum has already produced data showing that its lead candidate SDC-1801 is superior to Dexamethasone in a trial.

3. Sareum has shown that its science in combo with Astra Zeneca's WEE1, Merck’s Keytruda, Eli Lilly's Gemcitabine works.

4. We've not had any significant "fails" in 20 years.

5. The Phase 1a trial includes a single ascending dose study, a multiple ascending dose study and a food effects study. If the results are as good as we expect - and all the news has been encouraging to date - a big pharma is likely to swoop in with a licencing deal.

6. We already know that the safety and pharmacokinetics data from the initial cohorts in Part 1 of the SDC-1801 trial indicate a favourable profile and fully support oral dosing of patients once daily.

7. We have been briefed that the full safety data from the Phase 1a trial is expected to be available during Q2. We are in this period, so news could come at any time.

In summary, those with a vision and a medium term strategy to "Mega Multi-Bag" are in the right place at exactly the right time at these prices.

And finally, a reminder that TPST went up over 3900% (yes X39) last September in just a few days when it announced favourable data.

Yes and great to see Bobbler predicting 40p next. He's one to listen to, if you are a newbie. A few posters on here like Bobbler, RMM, Brighty etc nailed it during 2020 and 2021 with their predictions of 450p (post consolidation) a share. These & others were posting from sub 1p about the likely timescale of hitting 2p, 4p, 8p, 9p (450p) etc and do you know what? Their predictions were 100% right. Bobbler is someone who has got it spot on in the past and has demonstrated that he understands how this share price fluctuates just prior to news. Excellent to see him posting his predictions again.

Yes and you only have to see what happened to a similar bombed out share price with Tempest Therapeutics to see what’s possible. They had dropped to an all-time low (just like Sareum) and then positive data was revealed that saw the share price surge by x 39 in 1 week last September. BIG gains happen in this sector. We know that because SAR has already gone up x 46 before. If the data is positive it will start the firing gun for big pharma to do a licencing deal. At that stage our share price will then rocket. We are on the launch pad!

Yes SAR will be flying soon in readiness for the P1a data from Oz, if history is to be repeated. The SAR share price has always been cylical and has a tendency to rise significantly before trial news and then it just keeps climbing. Plus, remember SAR won't need any cash for years if a licencing deal for SDC-1801 is secured for a P2 trial with a major pharma. We've all seen the kind of money big pharma pays for partnering small bios. It's often in the tens of millions.

Yes, a move from P1 to P2 would see the value of Sareum increase exponentially as it would be a validation that the topline P1a trial had proven to be a success. Don't forget that Sareum has already produced data showing that its lead candidate SDC-1801 is superior to Dexamethasone in a trial. This is the same SDC-1801 that we are awaiting data on.

Yes and it's worth pointing out to the uninitiated that BIG gains happen in the pharma sector. We know that because SAR has already gone up x 46 before. That’s a fact.

If the data is positive it will start the firing gun for big pharma to do a licencing deal. At that stage our share price will then rocket.

You only have to see what happened to a similar bombed out share price with Tempest Therapeutics to see what’s possible. They had dropped to an all-time low (just like Sareum) and then positive data was revealed that saw the share price surge by x 39 in 1 week last September. That’s a fact. Have a great weekend.

Five months ago AZ also paid another small bio, Eccogene, $185m upfront, following encouraging prelim results of Eccogene's Phase I trial of ECC5004. The deal also included up to $1.825bn in future clinical, regulatory plus commercial milestones and tiered royalties on product sales. That would do nicely! i.e. AZ (Or ANother such as GSK or J&J) could swoop in with a licencing deal for SDC-1801 if the preliminary results are good. The clock is ticking.

A reminder everyone that in 2023 AZ paid an upfront payment of $63m for KYM Bio's Phase I clinical candidate CMG901 and agreed additional milestone development and sales-related payments of up to $1.1bn. It's what we are all here for with SDC-1801, SRA-737 and SDC-1802. i.e. Big pharma pay big bucks for P1 candidates. Sareum's SDC-1801 could be next.

Yes, this is a very interesting & exciting small MCAP business. The multi-bag potential on good drill news with KoBold could be huge and very similar to what happened at GGP. We know how that panned out: Those that invested in GGP in the 0.55 days saw a x 65 increase in their holding to over 35p a share. TYM's share price could be going vertical soon!

News, 2p a share initially on a KoBo JV drill success but if these licences do prove to have copper - and we are just weeks away from finding out with Konkola West - you are looking at more like 6-8p a share and maybe even 10p+ for a takeover based on all the licences in Zambia, Nevada and Sweden.

StayLong, your 14 points why Norway's largest financial services group, DNB ASA has bought a 4.89% piece of the DGI pie was excellent. You missed the biggie though ! Tesla went from $1 USD to $350 USD. That's why DNB ASA has invested. They will be the first of many from the Tesla Trio's black book to buy in to DGI moving forward. I'm with you on the huge upside here. DGI is a 3-5 year investment for similar mega gains. Over the next 12-18 months this is very likely multi-bag at least x 10 but over time this could be one of those x 100 "Mega Multi Baggers". I'm here for the long term as I'm sure you, DNB ASA & many others will be. i.e. DGI has the opportunity to be a $Billion Mcap company.

If these licences prove to have copper - and we are just weeks away from finding out with KoBo's JV drill at Konkola

West - you are looking at more like 6-8p a share and maybe even 10p+ for a takeover based on all the licences in Zambia, Nevada and Sweden.

Yes, its the Johnson & Johnson annual $7.5 Billion psoriasis treatment patent ending in 2025 that is piquing my interest the most. Remind me again, what is the SDC-1801 trial in Oz focusing on? Oh yes, psoriasis. Cha-ching!

Yes, RiverFort subscribing for a total of 1,106,986 new ordinary shares at 10 pence a share = £110,698.60 to Sareum. Happy days!

Yes and good to see the back of Yeo, Wakefield and Ford recently. Those Jon Ford Dunrobin briefings from his garden shed were excruciating to watch. Lets just see Boil focus on the BIG prize of Chuditch. However, it should be noted the huge salaries those 3 took out of the BOIL business.

yes, gold in trench t2 yielding values up to 2.7g/t gold. also in trench t11 ****nic and mercury are at 1,000 times background! this just gets better by the day. whilst all eyes are on the konkola west copper project in zambia this could be "transformational" news too. as you say, this is a bonus that could create a huge money making venture for tertiary minerals and its investors.

Yes, but to facilitate the Christian Eidem share purchase of 29+% of DGI shares in December Martin Boughtwood reduced his overall holdings from 3,026,591,664 shares to 465,954,554 shares or in percentage terms 4.5% of DGI. People appear to be getting mixed up on this. The RNS is about Martin Boughtwood's wife selling shares not Martin Boughtwood himself.